The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
Thanks Martyn
Just looked and it seems we should get a half year report at the end of July. I’ll be topping up with anything below 50p that’s for sure.
Very fair and constructive points all I’m saying is long term this is very undervalued. The traders will come back once this bottoms out. When can we expect more news t prop up the SP who knows. May be a while till we get June’s cash flows.
I personally see this as oversold and has been chucked in as just another loan company with high risk. But as you say we know that they are still operating at over 80% collections from pre covid levels. Yet the SP was 160 pre Covid and here we sit at 52p. Huge upside here and covid won’t last forever. Aslong as the company can keep showing over 80% of business still operating normally I see limited risk. Their digital business also helps to mitigate this risk. The main risk is people not being able to pay their loans but the company have also adjusted their customer base to higher credit ratings. I see at least 100 % here in 12 months and more long term. The countries that they operate in have also seen limited increases in cases of COVID except for Mexico. Undoubtedly if a second wave hits the SP will react accordingly but the underlying business may still be able to operate at over 80% of pre covid levels.
Anybody on L2? What does the book look like?
Will it bounce off 54 again .... ? Waiting for a top up not sure whether to wait till 50 or now.
Everyone chill RNS will come when it comes, highly likely this week. Glad we have changed the trend and this should keep going up as more fundamentals and sales orders are revealed. It’s never a straight line, put the kettle on or go for a walk.
AZ are helping Novacyt with progressing the tests. AZ are working with Novacyt to use saliva samples instead of the normal swabs for their employees as easier to use. As GGGG and I have already said the PCR test can already be used with saliva samples but do not currently have approved. I imagine the roll out in July with AZ employees will go towards data collection sent in for approval of using saliva samples with Novacyt PCR test however this is yet to be confirmed. Hopefully that clears that up. Check my previous posting history I’m an AZ employee. This company will be worth a huge amount more come Q4 and 2021.
Well there's been 50k shares sat on the ask at about 2.86 euros for most of the afternoon and every rise gets sold into so quite a bit of evidence there is still some overhang of sellers but it does seem to be easing was what I was trying to say.
I agree Obelix, the SP is driven mostly by the french market due to the majority of shares being traded there, every drop has been bought into for the french market, bodes well. Something is coming and I think the benefit of less overhang from a seller is helping.
Scottie the way I see it is the press have moved on to the new tests coming out for a new story such as antibody with ODX etc. The great thing about NCYT is that due to its high specificity and sensitivity making it the gold standard means any point of contact test positive will likely have to have the gold standard afterwards to make sure it is actually a positive and that the patient has the virus right now. This applies for both post antigen and antibody tets. We own that side of the market and the cost of our test will be higher than the point of contact tests but will also give more profit and rightly so because it’s a more sensitive and accurate test. This means NCYT will still be the gold standard even after all these tests are released. I’ve been in pharma a while and it’s very hard to displace a trusted and established gold standard once in place. The fact we have high throughout, direct to PCR and mobile testing shows we are adapting. In summary don’t worry about the media talking about the new tests because most positive readings will have to be double checked by ours. Obviously in some cases the patient will just have a Novacyt test because why bother doing 2 tests when you can do one? The new tests are to help with mass point of contact at home testing. People need to understand the two different markets. AZ are backing us and will be helping with a saliva PCR test to once again show we are adapting with changing environment as swabs up the nose are a bit more hassle for the patient.
Codey it’s quite obvious that the SP hasn’t moved up because of a large seller or shorter. Every time good need is released the SP roses and then gets hammered with sells. The fundamentals are improving every week just sit tight and the selling/shorting will end and this will rerate.
I know that we have the tech to run saliva PCR tests but does anyone know if there are any plans to produce a test kit that takes saliva as well as the swab up the nose? Surely it wouldn’t be that difficult to adjust our current test kit and would be a better way of collecting the sample. I’ve heard AZ are developing their own saliva test for employees so maybe making in conjunction with NCYT. Still long and strong as should see the benefits of upping to 10 million test per month in Julys report and that little matter of the US AND whether the French may change their view on reimbursement .....